Bruce C.  Cozadd net worth and biography

Bruce Cozadd Biography and Net Worth

Co-Founder, Chairman & CEO of Jazz Pharmaceuticals
Bruce C. Cozadd brings extensive experience in research and development, manufacturing and sales and marketing. After being inspired by the culture at ALZA where he started his career, Mr. Cozadd wanted to start a company where top talent can do their best and work inclusively as a team. It was under these ideals that Mr. Cozadd co-founded Jazz Pharmaceuticals Inc. in 2003.

Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on its Health Section Governing Board. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.

What is Bruce C. Cozadd's net worth?

The estimated net worth of Bruce C. Cozadd is at least $60.74 million as of March 3rd, 2025. Mr. Cozadd owns 464,058 shares of Jazz Pharmaceuticals stock worth more than $60,735,911 as of March 26th. This net worth evaluation does not reflect any other assets that Mr. Cozadd may own. Additionally, Mr. Cozadd receives a salary of $2,440,000.00 as Co-Founder, Chairman & CEO at Jazz Pharmaceuticals. Learn More about Bruce C. Cozadd's net worth.

How old is Bruce C. Cozadd?

Mr. Cozadd is currently 60 years old. There are 6 older executives and no younger executives at Jazz Pharmaceuticals. Learn More on Bruce C. Cozadd's age.

What is Bruce C. Cozadd's salary?

As the Co-Founder, Chairman & CEO of Jazz Pharmaceuticals plc, Mr. Cozadd earns $2,440,000.00 per year. Learn More on Bruce C. Cozadd's salary.

How do I contact Bruce C. Cozadd?

The corporate mailing address for Mr. Cozadd and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at investorinfo@jazzpharma.com. Learn More on Bruce C. Cozadd's contact information.

Has Bruce C. Cozadd been buying or selling shares of Jazz Pharmaceuticals?

During the last quarter, Bruce C. Cozadd has sold $1,306,235.00 in Jazz Pharmaceuticals stock. Most recently, Bruce C. Cozadd sold 6,500 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $144.25, for a transaction totalling $937,625.00. Following the completion of the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at $66,940,366.50. Learn More on Bruce C. Cozadd's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 42,062 shares worth more than $5,557,806.35. The most recent insider tranaction occured on March, 10th when CAO Patricia Carr sold 1,140 shares worth more than $157,103.40. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 3/10/2025.

Bruce C. Cozadd Insider Trading History at Jazz Pharmaceuticals

Bruce C. Cozadd Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Bruce C Cozadd's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.31MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $130.88
Low: $128.03
High: $134.90

50 Day Range

MA: $132.19
Low: $120.07
High: $144.17

2 Week Range

Now: $130.88
Low: $99.06
High: $148.06

Volume

1,801,184 shs

Average Volume

705,584 shs

Market Capitalization

$7.95 billion

P/E Ratio

18.43

Dividend Yield

N/A

Beta

0.44